Posted inClinical Updates Oncology
Non-Inferiority of a Simplified 14-Day Trifluridine-Tipiracil plus Bevacizumab Regimen for Refractory Metastatic Colorectal Cancer: Insights from the PRABITAS Trial
The PRABITAS trial demonstrated that a 14-day trifluridine-tipiracil plus bevacizumab regimen is non-inferior to the conventional 28-day schedule in refractory metastatic colorectal cancer, with significantly reduced hematological and gastrointestinal toxicities.